MedX Health Corp. Announces Proposed Private Placement to Raise $203,000
December 20 2013 - 4:35PM
Marketwired
MedX Health Corp. Announces Proposed Private Placement to Raise
$203,000
MISSISSAUGA, ONTARIO--(Marketwired - Dec 20, 2013) - MedX Health
Corp. ("MedX" or the "Company") (TSX-VENTURE:MDX) announces that it
has entered into private placement agreements with accredited
investors to raise a total of $203,000 by issuance of a total of
2,030,000 Units at $0.10 per unit. Each Unit comprises one fully
paid common share and one share purchase warrant; each warrant
entitles the holder to purchase one additional share at the price
of $0.20 during the period expiring December 31, 2014. Closing of
the Placement is subject to all relevant regulatory and other
consents and approvals, including acceptance by the TSX Venture
Exchange.
MedX presently has 57,714,657 common shares issued and
outstanding.
About MedX
MedX is headquartered in Mississauga, Ontario (Toronto), and is
a global leader in the design, manufacturing and distribution of
quality low level laser and light therapy technologies for use in
numerous medical settings, including rehab/chiropractic, dental,
wound care, and veterinary medicine, providing patients with drug
free and non-invasive treatment of tissue damage and pain. MedX
laser and light products are FDA approved, Health Canada cleared,
and CE Mark approved for use in North America as well as the
European Union. MedX's products include SIMSYS™ and MoleMate™,
which are approved by Health Canada, and available to Canadian
physicians and dermatologists, are FDA approved for use in the USA
and are currently under review for CE approval for use in Europe,
the UK, and Australia, as an optical biopsy that uses patented
technology featuring a hand-held scanner device designed for
clinical use that utilizes light to view beneath suspicious moles
or lesions in a pain free, non-invasive manner, creating images in
real-time for physicians and dermatologists to evaluate all types
of moles or lesions within seconds. For more information log onto:
www.simsys-molemate.com. For a complete profile of MedX and its
products visit www.medxhealth.com.
This press release does not constitute an offer of any
securities for sale. This press release contains certain
forward-looking statements within the meaning of applicable
Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual
results to differ, including, without limitation, the company's
limited operating history and history of losses, the inability to
successfully obtain further funding, the inability to raise capital
on terms acceptable to the company, the inability to compete
effectively in the marketplace, the inability to complete the
proposed acquisition and such other risks that could cause the
actual results to differ materially from those contained in the
company's projections or forward-looking statements. All forward
looking statements in this press release are based on information
available to the company as of the date hereof, and the company
undertakes no obligation to update forward-looking statements to
reflect events or circumstances occurring after the date of this
press release.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
MedX Health Corp.Robert von der PortenPresident and CEO905 670
4428investor@medxhealth.comwww.medxhealth.com
Medx Health (TSXV:MDX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Medx Health (TSXV:MDX)
Historical Stock Chart
From Nov 2023 to Nov 2024
